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It is reported that anti-mycotic agents are effective
for the treatment of patients with atopic dermatitis.
We studied the in vitro effects of anti-mycotics on T
helper-1 and T helper-2 cytokine production in anti-
CD3 plus anti-CD28-stimulated T cells from atopic
dermatitis patients and normal donors. The amounts
of interleukin-4 and interleukin-5 secreted by anti-
CD3/CD28-stimulated T cells were higher in atopic
dermatitis patients than in normal donors. Azole
derivatives, ketoconazole, itraconazole, miconazole,
and nonazole terbina®ne hydrochloride, and tolnaf-
tate reduced interleukin-4 and interleukin-5 secretion
without altering that of interferon-g and interleukin-
2 in anti-CD3/CD28-stimulated T cells from both
atopic dermatitis patients and normal donors. The
azole derivatives were more inhibitory than nonazole
anti-mycotics. These anti-mycotics reduced the anti-
CD3/CD28-induced mRNA expression and pro-
moter activities for interleukin-4 and interleukin-5.
The 3¢,5¢-cyclic adenosine monophosphate analog
dibutyryl 3¢,5¢-cyclic adenosine monophosphate
reversed the inhibitory effects of the anti-mycotics
on interleukin-4 and interleukin-5 secretion, mRNA
expression, and promoter activities. Anti-CD3/CD28
transiently (< 5 min) increased intracellular 3¢,5¢-
cyclic adenosine monophosphate in T cells, and the
increase was greater in atopic dermatitis patients
than in normal donors. The increase of 3¢,5¢-cyclic
adenosine monophosphate by anti-CD3/CD28 cor-
related with interleukin-4 and interleukin-5 secretion
by anti-CD3/CD28. The transient 3¢,5¢-cyclic adeno-
sine monophosphate increase was suppressed by
anti-mycotics, and azole derivatives were more sup-
pressive than nonazoles. Azole derivatives inhibited
the activity of cyclic adenosine monophosphate-
synthesizing adenylate cyclase whereas terbina®ne
hydrochloride and tolnaftate enhanced the activity of
3¢,5¢-cyclic adenosine monophosphate-hydrolyzing
cyclic nucleotide phosphodiesterase in atopic derma-
titis and normal T cells. These results suggest that
the anti-mycotics may suppress interleukin-4 and
interleukin-5 production by reducing 3¢,5¢-cyclic
adenosine monophosphate signal, and stress their
potential use for the suppression of T helper-2-medi-
ated allergic reactions. Key words: adenylate cyclase/
cyclic adenosine monophosphate/cyclic nucleotide phospho-
diesterase J Invest Dermatol 117:1635±1646, 2001
I
t has recently been reported that systemic and/or topical
treatment with anti-mycotics, especially azole derivatives
such as ketoconazole, is effective for patients with atopic
dermatitis (AD) (Clemmensen and Hjorth, 1983; Back et al,
1995; Broberg and Faergemann, 1995). This is partly caused
by the fungicidal or fungistatic effects of these agents, such as the
inhibition of ergosterol synthesis, cell membrane damage, disrup-
tion of microtubule function, or accumulation of squalene
(Elewski, 1993; Agut et al, 1992), as skin-localized fungi such as
Malassezia furfur may act as allergens for IgE-mediated allergic
responses in AD (Tengvall Linder et al, 1996). Additional
mechanisms unrelated to fungi, however, may also exist in the
therapeutic ef®cacy of anti-mycotics on AD; ketoconazole inhibits
the synthesis of leukotrienes via inhibiting 5-lipoxygenase in
polymorphonuclear leukocytes (Bettens et al, 1986); also, this effect
may contribute to the attenuation of AD symptoms as the synthesis
of leukotriene B4, which induces cutaneous in¯ammation, is
enhanced in AD skin lesions (Fogh et al, 1989). Ketoconazole also
inhibits lipopolysaccharide-induced expression of the nitric oxide
synthase gene and consequently inhibits reactive radical nitric oxide
production in macrophages, which may explain the anti-erythema
and anti-edema action of ketoconazole (Baroni et al, 1999). Other
immunomodulatory effects of anti-mycotics have also been
reported; ketoconazole inhibited the interleukin (IL)-2-dependent
proliferation of human T cell clones or proliferation of human
peripheral blood mononuclear cells in allogeneic mixed lympho-
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cyte culture (Pawelec et al, 1991a). Another azole derivative
itraconazole also inhibited the generation of allospeci®c cytolytic
activity in human mixed lymphocyte culture (Pawelec et al, 1991b).
It is thus anticipated that anti-mycotics may modulate certain
aspects of allergic immune responses in AD and thus alleviate the
symptoms of AD.
It has been proposed that T helper (Th)-2-type cytokines, such
as IL-4, IL-5, IL-10, or IL-13, play key pathogenetic roles in AD
(Grewe et al, 1998); T cells from AD patients predominantly
produce Th2 type cytokines in response to inhalant allergens such
as house dust mite (Wierenga et al, 1991). In particular, IL-4
enhances IgE synthesis and IL-5 favors the differentiation of
eosinophils; the overexpression of these two cytokines may induce
the increased serum IgE levels and blood eosinophilia in the
majority of AD patients (Grewe et al, 1998). In contrast, previous
studies reported that the production of Th1 type cytokines, such as
interferon (IFN)-g, by T cells in AD patients was reduced
compared with that in nonatopic donors (Reinhold et al, 1990;
Rousset et al, 1991; Katagiri et al, 1997).
The recent successful results in the treatment of AD patients with
anti-mycotics indicate that these agents may manipulate the
production of Th1 and/or Th2 cytokines in AD patients. It is
reported that treatment with ketoconazole reduced the serum IgE
level in AD patients (Back et al, 1995), indicating that ketoconazole
may suppress the production of Th2 cytokines promoting IgE
synthesis, such as IL-4 or IL-13, and/or upregulate the production
of Th1 cytokines inhibiting IgE synthesis, such as IFN-g. The
treatment with anti-mycotics amphotericin B or ¯uconazole
decreased IL-4 production and increased that of IFN-g in
Candida albicans-infected mice, alone or in combination with
anti-IL-10, soluble IL-4 receptor, or recombinant IL-12 (Cenci et
al, 1997; Mencacci et al, 2000). The treatment with new azole anti-
mycotics SCH 42427 or SCH 39304 also reduced serum IgE level
in Paracoccidioides brasiliensis or Blastomyces dermatidis-infected mice,
respectively, suggesting the suppression of Th2 responses by these
agents (Brummer et al, 1993; Hostetler et al, 1993).
In this study, we examined the in vitro effects of anti-mycotics on
the production of Th2 cytokines, IL-4 and IL-5, and Th1
cytokines, IFN-g and IL-2 in anti-CD3 plus anti-CD28-stimulated
T cells from AD patients, and the effects were compared with those
in nonatopic donors. The anti-mycotics examined were azole
derivatives, ketoconazole, itraconazole, miconazole, and nonazole
anti-mycotics, terbina®ne hydrochloride and tolnaftate, which are
often used topically or systemically for the treatment of AD. We
have obtained the results that these agents reduced Th2 cytokine
production without altering that of Th1. We further analyzed the
mechanism for the inhibitory effects focusing on the 3¢,5¢-
adenosine cyclic monophosphate (cAMP)-mediated signaling path-
ways in T cells.
MATERIALS AND METHODS
Patients and controls We studied 15 patients with mild to severe AD
[eight men and seven women, age 25.7 6 2.4 y (mean 6 SEM)],
diagnosed according to the criteria by Hani®n and Rajka (1980). Their
disease severity was scored according to the grading by Rajka and
Langeland (1989), and the score was 5.2 6 0.6 (mean 6 SEM). The
patients' serum total IgE value was 4658 6 1707 U per ml
(mean 6 SEM). At the time of the study, 12 of 15 patients were treated
with topical corticosteroids of mild to very strong rank. No patients
were taking systemic corticosteroids, anti-allergic or antihistaminic drugs,
or receiving desensitization immunotherapy. Fourteen nonatopic healthy
volunteers [seven men and seven women, age 25.9 6 2.1 y
(mean 6 SEM)] were studied as controls. None of the controls had
symptoms indicative of allergic diseases, or receiving medication, and
their serum total IgE value was 74 6 11 U per ml. At the time of the
investigation, all the patients and controls did not have active infection
by fungi, viruses, or bacteria, and were not receiving topical or systemic
anti-mycotic medication, and consumed no beverage containing caffeine
or methylxanthine for at least 8 h before drawing blood. All the patients
and controls were informed of the objectives and methods of this study,
and consented to participate.
Reagents Anti-CD3 monoclonal antibody (OKT3, murine IgG2a)
and anti-CD28 monoclonal antibody (clone 9.3, murine IgG2a)
were purchased from Becton Dickinson (San Jose, CA). Dibutyryl
cAMP (Bt2cAMP), dibutyryl 3¢,5¢-cyclic guanosine monophosphate
(Bt2cGMP), forskolin, N-[2-((p-bromocinnamyl)aminoethyl)-5-
isoquinolinesulfonamide (H-89), 1-oleoyl-2-acetyl-sn-glycerol (OAG),
and 3-isobutyl-1-methylxanthine were obtained from Calbiochem (La
Jolla, CA). Ketoconazole and itraconazole were from Janssen
Pharmaceutica NV (Beerse, Belgium). Miconazole was provided by
Mochida Pharmaceutical (Tokyo, Japan). Terbina®ne hydrochloride was
from Novartis Pharma (Tokyo, Japan). Tolnaftate was from Yamanouci
Pharmaceutical (Tokyo, Japan). These agents were dissolved in
dimethylsulfoxide as 10 mM stock solution and were kept in the dark
until used.
Human T cells and T cell line Peripheral blood mononuclear cells
from AD patients and normal donors were isolated by centrifugation
over Ficoll-Paque (Pharmacia, Uppsala, Sweden) as described (Boyum,
1968), and were allowed to adhere to plastic dishes for 1 h at 37°C.
From the nonadherent cells, CD56± cells were isolated by negative
selection using immunomagnetic beads (Dynal, Great Neck, NY) as
described (Gee et al, 1987), and were incubated with neuraminidase-
treated sheep erythrocytes as described (Farrant et al, 1985). From the
rosette-forming cells, CD14± and CD19± cells were isolated by the
immunomagnetic negative selection, and were used as T cells. This T
cell population was > 98% CD3+, and the contamination of CD14+,
CD19+, or CD56+ cells was < 2%.
Human Jurkat T cells were purchased from Dainippon Pharmaceutical
(Osaka, Japan), and were maintained in RPMI 1640 (Gibco/BRL,
Grand Island, NY) supplemented with 10% fetal bovine serum, 100 U
penicillin per ml, and 100 mg streptomycin per ml.
Measurement of cytokine secretion T cells (2 3 106 cells per ml)
were preincubated with or without various anti-mycotics at indicated
concentrations for 30 min, and seeded at the density of 4 3 105 per well
in triplicate to anti-CD3 plus anti-CD28-precoated plates as described
(Li et al, 1999a); the plates were coated by 100 ml of 10 mg anti-CD3
per ml plus 1 mg anti-CD28 per ml at 37°C for 1 h. The cells were
incubated for another 48 h in 200 ml per well of culture medium at
37°C in the presence or absence of respective anti-mycotics in an
atmosphere of 5% CO2. We used endotoxin-, hormone-, and serum-free
medium, 1:1 mixture of Dulbecco's minimal Eagle's medium (DMEM)
and Ham's Nutrient Mixture F-12 (DMEM/F-12) (Sigma, St. Louis,
USA), supplemented with 2.5 mM L-glutamine (Gibco/BRL). The
activity of IL-2, IFN-g, IL-4, and IL-5 in the culture supernatants was
measured by enzyme-linked immunosorbent assay (ELISA) kits
(Biosource, Tokyo, Japan) according to the manufacturer's instructions.
The sensitivity of the assay for IL-2, IFN-g, IL-4, and IL-5 was 5, 4, 3,
and 4 pg per ml, respectively.
Reverse transcription±polymerase chain reaction (reverse
transcription±PCR) T cells were incubated under the conditions
indicated, and total cellular RNA was extracted using mRNA
puri®cation kit (Pharmacia) according to the manufacturer's instructions.
cDNA was made from RNA samples as described (Llorente et al, 1994).
Primer sequences for cytokines and for the internal control b-actin as
well as PCR conditions are as described (Kanda and Watanabe, 2001).
The PCR products were analyzed by electrophoresis on 2.5% agarose
gels and stained with ethidium bromide. The intensity of the reverse
transcription±PCR products for cytokines and b-actin was determined
by densitometry (Hoefer Scienti®c Instruments, San Francisco, CA).
Results are expressed for each cytokine product as the ratio relative to b-
actin product.
Measurement of cAMP amount T cells were cultured under the
indicated conditions, and were harvested and lyzed with ethanol. The
cell lysates were centrifuged and the supernatants were dried under
vacuum. The dried samples were dissolved in acetate buffer (pH 5.8),
and cellular cAMP contents were measured with an ELISA kit from
Amersham (Arlington Heights, IL) according to the manufacturer's
instructions. The sensitivity of the assay was 12 fmol per assay well. The
cellular cAMP level was presented as pmol per 106 cells.
Measurement of cyclic nucleotide phosphodiesterase (PDE)
activity T cells were cultured under the indicated conditions, and
were lyzed in the buffer containing 20 mM Tris±HCl (pH 7.4), 1 mM
ethylenediamine tetraacetic acid, 1 mg aprotinin per ml, 1 mg pepstatin
per ml, 1 mg leupeptin per ml, 15 mM benzamidine, and 3.75 mM b-
mercaptoethanol. PDE activity of the cell lysate was assayed as described
(Robicsek et al, 1991) using 1 mM [2,8-3H] cAMP (30 Ci per mmol)
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(Amersham) as a substrate. The assays were performed in 40 mM Tris±
HCl (®nal pH 8.0), 10 mM MgCl2 at 37°C for 10 min, and PDE
activity was presented as pmol cAMP hydrolyzed per min per mg
protein.
Measurement of adenylate cyclase (AC) activity The T cell lysate
was centrifuged at 23,600 3 g for 10 min. The pellet was used as a
particulate fraction for AC assays as described (Salomon et al, 1974; Choi
et al, 1992). The AC activity of the particulate fraction was measured at
37°C for 10 min in 20 mM Tris±HCl (pH 7.4), 1 mM [a-32P]adenosine
triphosphate (30 Ci per mmol) (Amersham), 1 mM [3H]cAMP, 1 mM
3-isobutyl-1-methylxanthine, 5 mM MgCl2, 0.2 mM ethyleneglycol-bis-
(b-aminoethylether)-N,N,N¢,N¢-tetraacetic acid, 20 mM creatine
phosphate, and 100 units creatine phosphokinase per ml. AC activity was
presented as pmol cAMP formed per min per mg protein.
Plasmids and transfection pCAT3-basic vector carrying two SV40
poly(A) signals, one downstream of the CAT reporter gene, and the
other upstream of the multicloning site was purchased from Promega
(Madison, WI). The plasmid IL-2-CAT, which contains human IL-2
promoter (bp ±541 to +42 relative to the transcriptional start site), was
generated by PCR using human genomic DNA (Clontech, Heidelberg,
Germany) and primers based on the reported sequence (Siebenlist et al,
1986), and cloned into NheI/BglII site of pCAT3-basic vector. The
plasmids IFN-g-CAT, IL-4-CAT, or IL-5-CAT containing the
promoters of IFN-g (bp ±337 to +64), IL-4 (bp ±418 to +50), or IL-5
(bp ±511 to +4), respectively, were generated as described (Penix et al,
1993; Paliogianni et al, 1996; Mori et al, 1997). The entire cloned
regions were sequenced by the chain termination method and found to
be identical to the reported genomic sequences (Siebenlist et al, 1986;
Taya et al, 1982; Tanabe et al, 1987; Arai et al, 1989). Transfection of
Jurkat cells was carried out by the DEAE-dextran method as described
(Lee et al, 1993). Cells (107) were incubated with 10 mg DNA per ml
and 350 mg DEAE-dextran per ml (Pharmacia) in Tris-buffered saline for
30 min at room temperature. To decrease variations in transfection
ef®ciency, cells were transfected in single batches, which were then
separated into different drug treatment groups. Cells were washed with
Tris-buffered saline, and incubated with DMEM/F12. After 24 h, cells
were washed, preincubated with anti-mycotics for 30 min, and seeded to
anti-CD3/CD28-coated plates at a density of 4 3 105 cells per well, and
cultured in the presence or absence of the respective anti-mycotics in
200 ml of DMEM/F12. After 16 h, the cells were harvested and lyzed by
three freeze/thaw cycles. The cell lysate was centrifuged and supernatant
was assayed for CAT expression by CAT-ELISA (Roche Diagnostics,
Tokyo, Japan) according to the manufacturer's instructions. Total protein
amount was measured by a Bradford microassay procedure (Bio-Rad,
Hercules, CA). The expression of various CAT plasmids was presented
as pg CAT enzyme synthesized per mg total protein. pCAT3-control
vector (Promega) containing SV40 early promoter and enhancer
sequences was used as a positive control, and promoterless pCAT3-basic
vector was used as a negative control.
Assays of cAMP-dependent protein kinase [protein kinase A
(PKA)] The T cell lysate was assayed for the activity of PKA using
an ELISA kit (Medical and Biological Laboratories, Nagoya, Japan) by
examining the phosphorylation of plate-bound peptide substrate in the
presence or absence of 2 mM cAMP for 10 min at room temperature.
The plates were sequentially incubated with biotinylated antibody to the
phosphorylated substrate, peroxidase-conjugated streptavidin, o-
phenylenediamine, then the reaction was stopped, and optical density at
492 nm was read. The PKA activity was expressed as an activity ratio,
which is de®ned as the optical density in the absence of exogenous
cAMP divided by the optical density in the presence of cAMP added to
the assay.
Statistical analyses Student's t-test was used for the comparison of
mean amounts in AD and normal groups in Table I. One-way analysis
of variance with Dunnet's multiple comparison test was used for the data
in Figs 1 and 2. One-way analysis of variance with Scheffe's multiple
comparison test was used for the data in Figs 3(a±d) and (b, c) and
Table II and III. Spearman's correlation coef®cient was determined for
the data in Fig 5. A value of p < 0.05 was considered signi®cant.
RESULTS
The effects of anti-mycotics on anti-CD3/CD28-induced
IL-4, IL-5, IFN-g, and IL-2 secretion First, the effects of
various anti-mycotics were examined on anti-CD3/CD28-induced
secretion of Th1 and Th2 cytokines by T cells from AD patients
and normal donors. The anti-CD3/CD28-induced IL-4 secretion
was signi®cantly higher in AD patients than that in normal donors
(Table I). Azole derivatives, ketoconazole, itraconazole, and
miconazole and nonazole terbina®ne hydrochloride and tolnaftate
reduced the anti-CD3/CD28-induced IL-4 secretion in AD
patients' T cells in a concentration-dependent manner (Fig 1a);
percentage inhibition by 1 mM of ketoconazole, itraconazole,
miconazole, terbina®ne hydrochloride, or tolnaftate was 60%, 58%,
58%, 40%, and 38%, respectively. Thus the inhibitory effects of
azole derivatives ketoconazole, itraconazole, and miconazole were
mostly equivalent, and were greater than those of nonazole
terbina®ne hydrochloride and tolnaftate. These anti-mycotics also
reduced the anti-CD3/CD28-induced IL-4 secretion in normal
donors' T cells to the extents comparable with those in AD
patients' T cells (Fig 1a). The percentage inhibition by 1 mM of
ketoconazole, itraconazole, miconazole, terbina®ne hydrochloride,
or tolnaftate was 62%, 58%, 57%, 42%, or 40%, respectively, in
normal donors' T cells. The anti-CD3/CD28-induced IL-5
secretion by T cells was also signi®cantly higher in AD patients
than in normal donors (Table I). The azole and nonazole anti-
mycotics also reduced the anti-CD3/CD28-induced IL-5
secretion, and the magnitude of the reduction was equivalent in
AD patients and in normal donors (Fig 1b); percentage inhibition
by 1 mM of ketoconazole, itraconazole, miconazole, terbina®ne
hydrochloride, or tolnaftate was 70%, 69%, 69%, 50%, or 49%,
respectively, in AD patients compared with 72%, 69%, 68%, 49%,
or 48%, respectively, in normal donors. Thus the anti-mycotics
signi®cantly reduced anti-CD3/CD28-induced IL-4 and IL-5
secretion of both AD and normal T cells, and azole derivatives
were more inhibitory than nonazole anti-mycotics. None of
ketoconazole, itraconazole, miconazole, terbina®ne hydrochloride,
and tolnaftate reduced the viability of T cells, which was > 95%
after 48 h of incubation with the anti-mycotics, as examined by the
trypan blue dye exclusion test.
The anti-CD3/CD28-induced IFN-g secretion in AD patients
was not signi®cantly different from that in normal donors
(Table I), and the secretion was not signi®cantly altered by azole
and nonazole anti-mycotics (Fig 1c). Though 1 mM of azole
derivatives, ketoconazole, itraconazole, and miconazole appeared
to increase the IFN-g secretion slightly (9±12%) in AD patients and
Table I. Anti-CD3/CD28-induced Th2/Th1 cytokine
secretion and anti-CD3/CD28-induced increase of cAMP
level and of PKA activity in T cells from AD patients and
normal donorsa
AD (n = 15) Normal (n = 14)
IL-4 (pg per ml) 235.6 6 24.2b 112.5 6 12.3
IL-5 (pg per ml) 461.3 6 42.1b 221.5 6 23.6
IFN-g (pg per ml) 812.5 6 92.3 1005.2 6 122.4
IL-2 (pg per ml) 1205.3 6 141.4 1376.5 6 151.2
cAMP (pmol per 106 cells) 5.4 6 0.6b 2.1 6 0.3
PKA (±cAMP/+cAMP)c 0.43 6 0.04b 0.17 6 0.02
aT cells from AD patients or normal donors were incubated in anti-CD3 plus
anti-CD28-precoated plates. The intracellular cAMP level and cell lysate PKA ac-
tivity were analyzed after 5 min, whereas cytokine secretion was assayed after
48 h, and the background values without anti-CD3/CD28 were subtracted.
Background IL-4 secretion without anti-CD3/CD28 was less than detectable level
in both AD and normal T cells. The background IL-5, IFN-g, or IL-2 secretion
was 5.4 6 1.6 pg per ml, 6.5 6 1.1 pg per ml, or 11.3 6 2.6 pg per ml in AD T
cells (mean 6 SEM, n = 15), whereas 4.5 6 0.7 pg per ml, 7.8 6 1.4 pg per ml,
or 11.9 6 2.1 pg per ml in normal T cells (mean 6 SEM, n = 14), respectively.
The background cAMP level was 1.8 6 0.2 or 2.0 6 0.3 pmol cAMP per 106
cells in AD or normal T cells, respectively.
bp < 0.05 vs values of normal donors, by Student's t test.
cThe PKA activity was expressed as an activity ratio, which is de®ned as the op-
tical density in the absence of exogenous cAMP divided by the optical density in
the presence of cAMP added to the assay. The background PKA activity was
0.20 6 0.04 or 0.21 6 0.04 in AD or normal T cells, respectively.
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normal donors, the increase was not signi®cant. The anti-CD3/
CD28-induced IL-2 secretion by T cells in AD patients was not
signi®cantly different from that in normal donors (Table I), and
the secretion was not signi®cantly altered by the anti-mycotics.
Thus azole and nonazole anti-mycotics did not affect anti-CD3/
CD28-induced secretion of Th1 cytokines. We next examined if
the anti-mycotics may alter mRNA expression for Th1 and Th2
cytokines.
The effects of anti-mycotics on anti-CD3/CD28-induced
mRNA expression for Th1 and Th2 cytokines As analyzed
by reverse transcription±PCR, ketoconazole, terbina®ne
hydrochloride, and tolnaftate reduced anti-CD3/CD28-induced
IL-4 and IL-5 mRNA expression at 6 h incubation of T cells from
AD patients (Fig 6). The magnitude of the inhibition by an azole
derivative ketoconazole on IL-4 and IL-5 mRNA expression was
higher than that by nonazole terbina®ne hydrochloride and
tolnaftate; percentage inhibition of IL-4/b-actin ratio by
ketoconazole, terbina®ne hydrochloride, or tolnaftate was 67%,
44%, or 39%, and that of IL-5/b-actin was 62%, 40%, or 41%,
respectively (Fig 6b). In contrast, none of the anti-mycotics altered
anti-CD3/CD28-induced IFN-g and IL-2 mRNA expression
(Fig 6a, b). The other azole derivatives, itraconazole and
miconazole reduced IL-4 and IL-5 mRNA expression to an
extent equivalent to that of ketoconazole without altering that of
IFN-g and IL-2 (data not shown). In normal donors' T cells, the
azole and nonazole anti-mycotics reduced anti-CD3/CD28-
induced IL-4 and IL-5 mRNA expression and did not alter that
of IFN-g and IL-2 (data not shown). These results in mRNA levels
paralleled those in protein secretion for Th1 and Th2 cytokines
(Fig 1), suggesting the pretranslational downregulation of Th2
cytokine production by the anti-mycotics. We then examined if
these anti-mycotics may exert their action at the transcriptional
level by analyzing the effects of the anti-mycotics on the promoter
activities for Th1 and Th2 cytokines.
The effects of anti-mycotics on promoter activities for Th1/
Th2 cytokines Human Jurkat T cells were transiently transfected
with plasmids containing human IL-2, IFN-g, IL-4, or IL-5
promoters driving CAT reporter gene. The transfected cells were
preincubated with ketoconazole, terbina®ne hydrochloride, or
tolnaftate for 30 min, washed, and incubated with anti-CD3/
CD28 in the presence of respective anti-mycotics. The promoter
activity was assessed by the expression of CAT enzyme. The
attempt to transfect fresh peripheral blood T cells was unsuccessful
(data not shown). As shown in Table II, the anti-mycotics reduced
Figure 1. Concentration-dependency for the effects of various anti-mycotics on anti-CD3/CD28-induced secretion of Th2 and Th1
cytokines. T cells from an AD patient or normal donor were preincubated for 30 min with medium alone or with medium containing anti-mycotics
at indicated doses, and seeded to anti-CD3 plus anti-CD28-precoated plates, and cultured in the presence or absence of respective anti-mycotics for
another 48 h. The culture supernatants were assayed for IL-4 (a), IL-5 (b), IFN-g (c), and IL-2 (d) by ELISA, and background cytokine secretion
without anti-CD3/CD28 was subtracted. Values are the mean 6 SD of triplicate cultures. The background IL-4 secretion without anti-CD3/CD28
was less than detectable level in both AD and normal T cells. The background IL-5, IFN-g, or IL-2 secretion was 5.7 6 0.6 pg per ml, 6.4 6 0.7 pg
per ml, or 10.3 6 1.0 pg per ml (mean 6 SD of triplicate) in AD T cells whereas 4.3 6 0.4 pg per ml, 7.9 6 0.7 pg per ml, or 11.2 6 1.1 pg per ml
in normal T cells, respectively. *p < 0.05 vs control cultures with anti-CD3/CD28 alone and without anti-mycotics, by one-way analysis of variance
with Dunnet's multiple comparison test. The data represent ®ve separate experiments using T cells from ®ve different AD patients and ®ve different
normal donors.
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the anti-CD3/CD28-induced IL-4 and IL-5 promoter activities,
and ketoconazole was more inhibitory than terbina®ne
hydrochloride and tolnaftate. In contrast, these anti-mycotics did
not alter the anti-CD3/CD28-induced IFN-g and IL-2 promoter
activities. The other azole derivatives itraconazole and miconazole
also reduced anti-CD3/CD28-induced IL-4 and IL-5 promoter
activities by the magnitude comparable with that of ketoconazole,
without altering IFN-g and IL-2 promoter activities (data not
shown). These results in transfection assays are consistent with those
in mRNA expression (Fig 6) and protein secretion (Fig 1) for
Th1/Th2 cytokines. It is thus suggested that the anti-mycotics may
reduce Th2 cytokine production at the transcriptional level,
although post-transcriptional regulation is also implicated.
CAMP-induced reversal from the anti-mycotic-induced
inhibition on IL-4 and IL-5 production It is known that
anti-mycotics, especially azole derivatives modulate a variety of
intracellular signaling pathways via regulating intracellular enzyme
activity (Beetens et al, 1986; Janssen et al, 1989; Stalla et al, 1989;
Hegemann et al, 1993). Thus the anti-mycotics may repress anti-
CD3/CD28-induced IL-4 and IL-5 production by inhibiting
certain signaling pathways required for the production. To identify
the target signal(s) for the anti-mycotics, we examined if several
signal-inducers may counteract the anti-mycotic-induced
repression of IL-4 and IL-5 production. The signal inducers were
cAMP analog Bt2cAMP which activates PKA, cGMP analog
Bt2cGMP activating cGMP-dependent protein kinase, and
diacylglycerol analog OAG activating protein kinase C. As shown
in Fig 3, these agents were added at low concentrations that did
not alter anti-CD3/CD28-induced IL-4 and IL-5 production in
the absence of anti-mycotics. Bt2cAMP reversed the ketoconazole-
mediated repression of IL-4 and IL-5 secretion in AD patients' T
cells (Fig 3a, b) and of IL-4 and IL-5 promoter activities in Jurkat
T cells (Fig 3c, d). As the intracellular cAMP is synthesized by AC
and hydrolyzed by PDE, cAMP can be increased by the stimulation
of AC and/or inhibition of PDE. The ketoconazole-mediated
inhibition of IL-4 and IL-5 secretion and of promoter activities
were also reversed by cAMP-elevating agents, AC activator
forskolin (1 mM) or PDE inhibitor 3-isobutyl-1-methylxanthine
(50 mM) (data not shown). Bt2cAMP (Fig 3e), forskolin, or 3-
isobutyl-1-methylxanthine (data not shown) also counteracted the
ketoconazole-mediated inhibition of IL-4 and IL-5 mRNA
expression in AD patients' T cells. These results indicate that the
cAMP/PKA signaling pathway may be involved in the
ketoconazole-mediated inhibition of IL-4 and IL-5 production.
On the other hand, Bt2cGMP or OAG did not counteract the
ketoconazole-induced inhibition on IL-4 and IL-5 secretion
(Fig 3a, b), promoter activities (Fig 3c, d), and mRNA
expression (Fig 3e), indicating that protein kinase C or cGMP-
dependent protein kinase may not be involved in the ketoconazole-
mediated inhibition of IL-4 and IL-5 production. The speci®c PKA
inhibitor H-89 reduced anti-CD3/CD28-induced IL-4 secretion
(Fig 3a) or promoter activity (Fig 3c) by 79% or 80%, and IL-5
secretion (Fig 3b) or promoter activity (Fig 3d) by 81% or 80%
compared with controls, respectively, suggesting that cAMP/PKA
signaling pathway may be required for anti-CD3/CD28-induced
IL-4 and IL-5 production. In the presence of H-89, ketoconazole
did not further reduce the anti-CD3/CD28-induced IL-4 and IL-5
secretion and promoter activities, which con®rms that cAMP/PKA
pathway may be the main target for the ketoconazole-mediated
inhibition of IL-4 and IL-5 production. On the other hand, H-89
did not alter anti-CD3/CD28-induced IFN-g and IL-2 secretion,
mRNA expression, and promoter activities (data not shown),
indicating that PKA may not be required for the production of Th1
cytokines. Bt2cAMP or cAMP-elevating agents also counteracted
the effects of itraconazole, miconazole, terbina®ne hydrochloride,
and tolnaftate on IL-4 and IL-5 secretion and mRNA expression in
AD patients' T cells and on IL-4 and IL-5 promoter activities in
Jurkat T cells (data not shown). In normal donors' T cells,
Bt2cAMP or cAMP-elevating agents also counteracted the effects
of ketoconazole, itraconazole, miconazole, terbina®ne
hydrochloride, and tolnaftate on IL-4 and IL-5 secretion and
mRNA expression induced by anti-CD3/CD28, and the anti-
mycotics did not further reduce the IL-4 and IL-5 production of
normal donors' T cells in the presence of H-89 (data not shown).
These results suggest that the anti-mycotic-induced inhibition of
IL-4 and IL-5 production may be attributable to the inhibition of
cAMP/PKA signaling pathway in both AD patients' and normal
donors' T cells. We then examined whether the anti-mycotics may
alter cAMP level in anti-CD3/CD28-stimulated T cells.
The effects of anti-mycotics on cAMP level in anti-CD3/
CD28-stimulated T cells We examined the kinetics of cAMP
level of T cells after incubation with anti-CD3/CD28 (Fig 4a).
Though the basal cAMP level was not different between AD
patients' and normal donors' T cells, the cAMP level of AD T cells
increased 4-fold above the basal level 5 min after the anti-CD3/
CD28 stimulus, whereas that of normal T cells increased 2-fold.
The anti-CD3/CD28-induced increase of cAMP at 5 min in AD T
cells was signi®cantly higher than that in normal T cells (Table I).
In both AD and normal T cells, the anti-CD3/CD28-induced
increase of cAMP correlated with anti-CD3/CD28-induced IL-4
and IL-5 secretion, although the correlation was greater in AD T
cells than in normal T cells (Fig 5). On the other hand, there was
no signi®cant correlation between anti-CD3/CD28-induced
cAMP increase and IFN-g or IL-2 secretion by anti-CD3/CD28.
These results indicate that the anti-CD3/CD28-induced increase of
cAMP may be required for IL-4 and IL-5 production, whereas
dispensable for that of IFN-g and IL-2. Ketoconazole, itraconazole,
or miconazole reduced the anti-CD3/CD28-induced increase of
cAMP by 75, 74, or 73%, whereas terbina®ne hydrochloride or
tolnaftate reduced the increase by 46 or 44% in AD T cells,
Figure 2. Concentration-dependency for the effects of various
anti-mycotics on AC and PDE activities. (a) AC activities; (b) PDE
activities. The particulate fraction of freshly isolated peripheral blood T
cells from an AD patient and normal donor was assayed for AC activity
(a), and the whole cell lysate was assayed for PDE activity (b) in the
presence or absence of indicated doses of ketoconazole, terbina®ne
hydrochloride, or tolnaftate. Values are the mean 6 SD of triplicate
assays. The data represent ®ve separate experiments using T cells from
®ve different AD patients and ®ve different normal donors. *p < 0.05 vs
values without anti-mycotics, by one-way analysis of variance with
Dunnet's multiple comparison test.
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respectively (Fig 4b). Thus the inhibitory effects on cAMP by azole
derivatives ketoconazole, itraconazole, and miconazole were
mostly equivalent and were greater than those by nonazole
terbina®ne hydrochloride and tolnaftate. The anti-CD3/CD28
enhanced PKA activity at 5 min in AD and normal T cells, and the
enhancement was greater in AD T cells than in normal T cells
(Table I), which paralleled the increase of cAMP. The anti-
mycotics suppressed the anti-CD3/CD28-induced activation of
PKA in AD patients' T cells (Fig 4c) in parallel with the reduction
of cAMP (Fig 4b). The magnitude of the suppression of PKA was
greater in azole ketoconazole, itraconazole, and miconazole than in
nonazole terbina®ne hydrochloride and tolnaftate (Fig 4c), which
paralleled the magnitude of the reduction of cAMP by each agent
(Fig 4b). In normal donors' T cells, the anti-mycotics suppressed
the anti-CD3/CD28-induced increase of cAMP and of PKA
activity, and azole derivatives were more suppressive than
nonazoles (data not shown). Thus the anti-mycotics suppressed
the cAMP signal induced by anti-CD3/CD28, and the suppressive
effects of azole derivatives ketoconazole, itraconazole, and
miconazole were greater than nonazole terbina®ne hydrochloride
or tolnaftate. As the reduction of cAMP level can be mediated by
the inhibition of AC and/or stimulation of PDE, we examined if
the anti-mycotics may alter AC and/or PDE activity.
The effects of anti-mycotics on AC and PDE activities of T
cells As shown in Table III, anti-CD3/CD28 increased AC
activity of AD or normal T cells 4.5-fold or 2.5-fold above the basal
level, respectively. Though the basal AC activity was not different
between AD and normal T cells (p > 0.10 by Student's t test), the
anti-CD3/CD28-promoted AC activity in AD T cells was
signi®cantly higher than that in normal T cells (p < 0.05 by
Student's t test). The anti-CD3/CD28-induced increase of AC was
suppressed by ketoconazole in both AD and normal T cells.
Ketoconazole also reduced the basal AC activity in the absence of
anti-CD3/CD28 in both AD and normal T cells. Itraconazole and
miconazole also suppressed the basal and anti-CD3/CD28-
promoted AC activity by the magnitude comparable with that of
ketoconazole in both AD and normal T cells (data not shown). In
contrast, terbina®ne hydrochloride and tolnaftate did not alter the
basal and anti-CD3/CD28-promoted AC activity in either AD or
normal T cells. The anti-CD3/CD28 also enhanced PDE activity
of AD or normal T cells 2.0-fold or 1.5-fold above the basal level
5 min after the stimuli, respectively, and terbina®ne hydrochloride
and tolnaftate promoted the basal and anti-CD3/CD28-enhanced
PDE activities in both AD and normal T cells, whereas those were
not altered by ketoconazole (Table III), itraconazole, and
miconazole (data not shown). These results suggest that
Figure 3. Bt2cAMP-mediated reversal from
ketoconazole-induced inhibition on IL-4 and
IL-5 secretion, promoter activities, and
mRNA expression induced by anti-CD3/
CD28. (a, b) T cells from ®ve different AD
patients were preincubated for 30 min with or
without Bt2cAMP 50 mM, Bt2cGMP 50 mM,
OAG 100 ng per ml, or H-89 0.1 mM in the
presence or absence of ketoconazole 1 mM, then
seeded on to anti-CD3 plus anti-CD28-precoated
plates, and cultured for another 48 h in the
presence or absence of the above-mentioned
agents. Cytokine secretion was analyzed by
ELISA, and background secretion without anti-
CD3/CD28 was subtracted. (c, d) Jurkat T cells
were transfected with IL-4 promoter-CAT
reporter (c) or IL-5 promoter-CAT reporter
plasmid (d). After 24 h, the transfected cells were
preincubated with indicated agents as above, then
incubated with plate-bound anti-CD3/CD28 in
the presence or absence of respective agents. After
16 h, IL-4 or IL-5 promoter activity was assayed
by CAT expression of the cell lysate. The data are
shown as percent vs the values in control cultures
with anti-CD3/CD28 alone, and represent the
mean 6 SEM of ®ve separate experiments. The
background IL-4 secretion and IL-4 and IL-5
promoter activities without anti-CD3/CD28 were
less than detectable level. The background IL-5
secretion was 5.5 6 0.6 pg per ml (mean 6 SEM,
n = 5). The anti-CD3/CD28-induced secretion
of IL-4 or IL-5 without the other agents was
232.5 6 26.3 or 447.3 6 54.6 pg per ml
(mean 6 SEM, n = 5), respectively. The anti-
CD3/28-induced IL-4 or IL-5 promoter activity
was 17.5 6 3.5 or 19.5 6 2.3 pg CAT per mg
protein (mean 6 SEM, n = 5), respectively. *p
< 0.05 vs cultures with anti-CD3/CD28 alone and
²p < 0.05 vs cultures with anti-CD3/CD28 plus
ketoconazole, by one-way analysis of variance
with Scheffe's multiple comparison test. (e) T cells
from an AD patient were preincubated with
indicated agents, and incubated with anti-CD3
plus anti-CD28 as described above. After 6 h,
RNA was extracted and reverse transcription±
PCR products were analyzed by electrophoresis.
The data represent ®ve separate experiments using
T cells from ®ve different AD patients.
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ketoconazole, itraconazole, and miconazole may suppress AC
activity, whereas terbina®ne hydrochloride and tolnaftate may
enhance PDE activity and thus may reduce cAMP levels in anti-
CD3/CD28-stimulated T cells from AD patients and normal
donors.
To know the direct effects of the anti-mycotics on AC or PDE
activity, we directly added each anti-mycotic to the reaction
mixture of AC or PDE assay. Ketoconazole reduced whereas
terbina®ne hydrochloride and tolnaftate did not alter AC activity of
T cell particulate fractions; the percent inhibition vs controls by
1 mM ketoconazole was 72% and 70% in AD and normal T cells,
respectively (Fig 2a). In contrast, terbina®ne hydrochloride and
tolnaftate enhanced, whereas ketoconazole did not alter PDE
activity of T cell lysates (Fig 2b); the percent stimulation vs controls
by 1 mM terbina®ne hydrochloride or tolnaftate was 95% or 80% in
AD T cells and 92% or 72% in normal T cells, respectively. The
other azole derivatives itraconazole and miconazole reduced AC
activities of particulate fractions from AD and normal T cells by the
magnitude similar to that of ketoconazole without altering PDE
activity (data not shown). These results suggest that azole
derivatives ketoconazole, itraconazole, and miconazole may sup-
press AC activity, whereas nonazole terbina®ne hydrochloride and
tolnaftate may stimulate PDE activity and thus suppress anti-CD3/
CD28-induced increase of cAMP in AD and normal T cells. The
suppression of cAMP signal may inhibit the activation of PKA,
which may result in the repression of IL-4 and IL-5 production.
AC-inhibiting ketoconazole, itraconazole, and miconazole were
more effective for the reduction of cAMP, and of IL-4 and IL-5
production than PDE-stimulating terbina®ne hydrochloride and
tolnaftate. On the other hand, the anti-mycotic-induced reduction
of cAMP may not reduce IFN-g and IL-2 production in both AD
and normal T cells (Fig 1), indicating that the cAMP signal by anti-
CD3/CD28 may not be required for the IFN-g and IL-2
production.
DISCUSSION
In this study, anti-mycotics reduced IL-4 and IL-5 production in
anti-CD3/CD28-stimulated AD and normal T cells without
altering that of IFN-g and IL-2. A previous study reported the
discrepant results; itraconazole and miconazole nondifferentially
inhibited phytohemagglutinin-induced mRNA accumulation for
IL-2, IL-4, and IFN-g in human peripheral blood mononuclear
cells (Friccius et al, 1992). Those nondifferential effects by
itraconazole and miconazole, however, occurred only at high
doses (10 mg per ml, i.e., 14.2 mM for itraconazole and 24 mM for
miconazole) and after extended incubation (24 h), whereas 6 h
incubation with these agents at 1 mM differentially suppressed anti-
CD3/CD28-induced mRNA expression for IL-4 and IL-5, and
not for IL-2 or IFN-g in our present study (Fig 6). Thus the
mechanism for the nondifferential inhibition by itraconazole and
Figure 4. Kinetics of intracellular cAMP level after anti-CD3/CD28 stimulus and anti-mycotic-mediated effects on anti-CD3/CD28-
induced increase of cAMP and of PKA activity in T cells. (a) T cells from an AD patient and a normal donor were incubated with plate-bound
anti-CD3 plus anti-CD28. Intracellular cAMP level was analyzed at the indicated time points. The mean 6 SD of triplicate cultures is shown. The data
are representative of ®ve separate experiments using T cells from ®ve different AD patients and ®ve different normal donors. (b) T cells from 15 AD
patients were preincubated with or without ketoconazole, itraconazole, miconazole, terbina®ne hydrochloride, or tolnaftate (each 1 mM) for 30 min,
and seeded on to anti-CD3 plus CD28-precoated or noncoated plates, and incubated in the presence or absence of respective anti-mycotics. After
5 min, the cells were harvested and assayed for cAMP level (b) or PKA activity (c). The data are mean 6 SEM (n = 15). *p < 0.05 vs values without
anti-CD3/CD28, and ²p < 0.05 vs values with anti-CD3/CD28 alone, by one-way analysis of variance with Scheffe's multiple comparison test.
Table II. The effects of anti-mycotics on the promoter
activities for Th2 and Th1 cytokinesa
CAT expression (pg CAT per mg protein)
IL-4 IL-5 IFN-g IL-2
CD3/CD28 19.6 6 2.2 17.4 6 1.8 55.8 6 5.3 65.6 6 6.2
CD3/CD28+
ketoconazole
7.0 6 0.8b 5.9 6 0.6b 56.1 6 6.1 66.3 6 6.1
CD3/CD28+
terbina®ne
hydrochloride
10.5 6 2.1bc 9.8 6 1.1bc 56.0 6 5.8 65.8 6 6.9
CD3/CD28+
tolnaftate
11.3 6 1.6bc 9.9 6 1.0bc 55.6 6 5.9 66.1 6 6.8
aJurkat T cells were transiently transfected with IL-4, IL-5, IFN-
g, or IL-2 promoter-CAT reporter plasmids, and preincubated with medium
alone or with ketoconazole, terbina®ne hydrochloride, or tolnaftate (each 1 mM)
for 30 min, and seeded to anti-CD3 plus anti-CD28-precoated plates, and cultured
in the presence or absence of respective anti-mycotics for 16 h. The activity of
each promoter was assessed by CAT expression of the cell lysate. The data are
mean 6 SD of triplicate assays, and are representative of ®ve separate experiments.
The CAT expression by each cytokine promoter-CAT reporter plasmid without
anti-CD3/CD28 was less than detectable level. The CAT expression by pCAT3-
control vector without stimuli was 192.5 6 17.8 pg CAT/mg protein, and that by
pCAT3-basic vector was less than detectable level.
bp < 0.05 vs values with anti-CD3/CD28 alone, and
cp < 0.05 vs values with anti-CD3/CD28 plus ketoconazole, by one-way analysis
of variance with Scheffe's multiple comparison test.
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miconazole in Friccius et al (1992) may differ from that for the
Th2-preferential inhibition in our study. The Th2-preferential
inhibition in our study was mediated by reducing anti-CD3/
CD28-induced cAMP signal. The inhibition of cAMP by azole
derivatives ketoconazole, itraconazole, and miconazole were
mediated by the inhibition of AC, whereas those of nonazole
terbina®ne hydrochloride and tolnaftate were mediated by the
stimulation of PDE. AC-inhibiting azole derivatives more effect-
ively reduced cAMP or IL-4 and IL-5 production than PDE-
stimulating terbina®ne hydrochloride or tolnaftate.
It is reported that the activation of the CD3 molecule leads to the
moderate but signi®cant increase of cAMP in T cells (Kvanta et al,
1990; Bihoreau et al, 1991). Though CD3 does not directly couple
to AC, the ligation of CD3 triggers the activation of phospholipase
C, and the phospholipase C-mediated signals activate AC
(Bihoreau et al, 1991; Kvanta et al, 1990). The activated
phospholipase C generates inositol 1,4,5-triphosphate and diacyl-
glycerol; the former induces the intracellular Ca2+ mobilization and
the latter activates protein kinase C (Bihoreau et al, 1991). It is
reported that Ca2+ forms a complex with cytosolic calmodulin and
the Ca2+/calmodulin complex binds to and activates AC catalytic
subunits, whereas protein kinase C activates AC catalysts by
phosphorylation (Bihoreau et al, 1991; Iyengar, 1993). Protein
kinase C-mediated phosphorylation may also downregulate the
activity of the inhibitory guanine-nucleotide-binding protein (Gi)-
a subunit, which binds to and inactivates AC catalysts (Gordeladze
et al, 1989; Chen and Iyengar, 1993), and/or promote the activity
of the stimulatory guanine-nucleotide-binding protein (Gs)-a
subunit, which binds to and activates AC catalysts (Bell et al,
1985), and both mechanisms may lead to the activation of AC. As
the stimulation of CD28 also triggers the activation of phospho-
lipase C (Nunes et al, 1993), the cross-linking of CD3 and CD28
may indirectly activate AC via phospholipase C-mediated signaling
pathways in T cells.
In this study, the anti-CD3/CD28-mediated increase of cAMP
correlated with the anti-CD3/CD28-induced IL-4 and IL-5
secretion, but did not correlate with that of IFN-g and IL-2. The
PKA inhibitor H-89 reduced the anti-CD3/CD28-induced IL-4
and IL-5 secretion, but not IL-2 and IFN-g. These indicate that the
anti-CD3/CD28-mediated cAMP signal appeared to be required
for the Th2 cytokine (IL-4 and IL-5) production while dispensable
for that of Th1 cytokines (IFN-g and IL-2). Previous studies also
reported that the cAMP signal stimulated Th2 cytokine produc-
tion, although some con¯icting data are also seen; cAMP-elevating
agents, prostaglandin E2 or cholera toxin, upregulated IL-4 and IL-
5 transcription in concanavalin A-primed and ionophore plus
phorbol myristate acetate-restimulated murine CD4+ T cells
(Lacour et al, 1994). Bt2cAMP activated the IL-5 promoter in
murine thymoma EL-4 cells in synergy with phorbol myristate
acetate (Lee et al, 1993). On the other hand, prostaglandin E2 did
not alter IL-4 production in murine thymoma EL-4 and Th2 cell
line D10.G4.1 (Novak and Rothenberg, 1990) or rather reduced
concanavalin A-induced IL-4 secretion in human peripheral blood
T cells (Borger et al, 1996). Thus the regulatory effects of cAMP on
Th2 cytokine production may vary depending on the T cell
activation status, costimulatory signals, and/or the elevated cAMP
level. Our present results indicate that anti-CD3/CD28-induced
Th2 cytokine production in human nonprimed T cells may require
the transient and moderate rise of cAMP, 2±4-fold of basal level.
The promotion of Th2 production by cAMP may possibly be
mediated by transcription factor GATA-3, whose binding sites exist
on IL-5 and IL-4 promoters and are especially indispensable for IL-
5 gene expression (Zhang et al, 1997); Bt2cAMP enhanced DNA-
binding activity of GATA-3 in murine Th2 clones (Zhang et al,
1997). Alternatively, cAMP may promote IL-4 and/or IL-5
transcription indirectly via another transcription factor CCAAT/
enhancer binding protein (C/EBP) whose binding sites exist on
human IL-4 and IL-5 promoters (Davydov et al, 1995; Cousins et
al, 2000). It is reported that cAMP induces the synthesis of C/
EBPb by activating cAMP response element binding protein
(CREB) via PKA as C/EBPb promoter contains CREB binding
sites (Niehof et al, 1997). cAMP also promotes the nuclear
translocation of C/EBPb via PKA-mediated phosphorylation
(Metz and Ziff, 1991; Chinery et al, 1997). Another possible
mechanism is that cAMP/PKA pathway may amplify the
autoinduction of IL-4 as IL-4 ampli®es IL-4 release from activated
CD4+ T cells (Lacour et al, 1994).
In contrast, Th1 cytokine production is suppressed by the
accumulation of cAMP. cAMP activates PKA and the PKA-
phosphorylated CREB and/or activating transcription factor-1
competitively inhibits the binding of activator protein-1 to the
IFN-g promoter and thus suppresses the promoter activity (Penix et
al, 1996). cAMP-activated PKA may alter the composition of
transcription factor complex, nuclear factor of activated T cells, to
an unfavorable form for the binding to IL-2 promoter (Lee et al,
1993; Tsuruta et al, 1995). cAMP also inhibits the binding of
nuclear factor kB (p50/p65) heterodimer to IL-2 promoter, which
may lead to the suppression of IL-2 transcription (Tsuruta et al,
Table III. The effects of anti-mycotics on AC and PDE activities of T cellsa
AC activityb PDE activityb
CD3/CD28 (±) CD3/CD28 (+) CD3/CD28 (±) CD3/CD28 (+)
AD patients
None 33.8 6 5.0 153.1 6 15.9 18.9 6 2.1 37.0 6 3.6
Ketoconazole 11.3 6 1.5 (±67)c 55.1 6 6.7 (±64)c 19.0 6 1.9 (0) 35.6 6 3.8 (±4)
Terbina®ne
hydrochloride
34.1 6 4.6 (1) 150.2 6 16.1 (±2) 34.5 6 4.6 (83)c 69.1 6 8.9 (87)c
Tolnaftate 34.0 6 5.1 (1) 148.4 6 16.1 (±3) 33.2 6 3.5 (76)c 65.3 6 8.6 (76)c
Normal donors
None 39.5 6 4.5 81.3 6 8.4 18.1 6 1.9 27.1 6 3.2
Ketoconazole 16.8 6 2.8 (±57)c 36.3 6 4.7 (±55)c 17.0 6 1.9 (±6) 25.6 6 3.5 (±6)
Terbina®ne
hydrochloride
39.1 6 4.0 (0) 84.2 6 9.1 (4) 31.9 6 4.9 (72)c 50.1 6 6.1 (85)c
Tolnaftate 38.9 6 3.6 (±1) 82.4 6 9.0 (1) 30.8 6 3.7 (70)c 47.2 6 5.0 (74)c
aT cells from 15 AD patients and 14 normal donors were preincubated with medium alone or with ketoconazole, terbina®ne hydrochloride, or tolnaftate (each 1 mM)
for 30 min, and seeded to anti-CD3 plus anti-CD28-precoated (+) or noncoated (±) plates, and incubated in the presence or absence of respective anti-mycotics for 5 min.
T cells were then harvested and assayed for AC and PDE activities. The data are mean 6 SEM (n = 15 for AD patients; n = 14 for normal donors). The values in parenth-
eses are the percent decrease or increase vs controls without anti-mycotics.
bpmol cAMP per min per mg protein.
cp < 0.05 vs controls without anti-mycotics, by one±way analysis of variance with Scheffe's multiple comparison test.
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1995). Thus Th1 cytokine production appears to be suppressed by
the excessive and prolonged accumulation of cAMP, e.g.,
prostaglandin E2 elevates intracellular cAMP up to 85-fold of
basal level (Snijdewint et al, 1993). The moderate and transient
cAMP increase by anti-CD3/CD28, however (Fig 4a), may not at
least suppress Th1 cytokine production as Th1 production was not
signi®cantly enhanced by the anti-mycotic-induced reduction of
cAMP (Fig 1c, d).
The anti-CD3/CD28-induced increase of AC activity and the
resultant cAMP signal were greater in AD T cells than in normal T
cells (Fig 4, Table III), and this may contribute to the enhanced
IL-4 and IL-5 secretion in the former. This indicates that AC in
AD T cells may be more sensitive to anti-CD3/CD28-mediated
signals, protein kinase C, and/or Ca2+, compared with that in
normal donors' T cells. This may possibly be due to the difference
in AC isoform composition between AD and normal T cells. To
date, eight different isoforms of AC have been isolated (Iyengar,
1993); protein kinase C stimulates AC types 2 and 7 (Jacobowitz
and Iyengar, 1994; Watson et al, 1994), and Ca2+/calmodulin
stimulates AC types 1 and 3, whereas Ca2+ directly inhibits AC
types 5 and 6 (Iyengar, 1993). In particular, protein kinase C
activates AC type 2 not only by direct phosphorylation of the
catalytic subunit but also by suppressing the inhibitory function of
Gi-2a on the catalyst (Chen and Iyengar, 1993). AC types 1 or 3
have not been detected in human T cells; however, several reports
support that AC in human T cells is activated by Ca2+/calmodulin
(Kvanta et al, 1990; Bihoreau et al, 1991). Thus the amounts of AC
types 2 and 7 and/or 1 and 3 may be increased and/or those of AC
types 5 and 6 may be reduced in AD T cells as compared with
normal T cells. It is also plausible that the protein kinase C
isoform(s), which can selectively phosphorylate AC catalysts and/or
Gi/Gs, may be more enriched in AD T cells; Gi-2 a is
phosphorylated by protein kinase C a and e but not by d
(Murthy et al, 2000), indicating the abundance of protein kinase C
a and/or e in AD T cells. Alternatively, AC catalysts and/or Gi/Gs
may be more accessible to the activated protein kinase C in AD T
cells; the phosphorylation sites of AC catalysts and/or Gi/Gs may
be more exposed in AD T cells and/or AD T cells may more
abundantly contain certain anchoring protein(s) termed receptor(s)
for activated C kinase, which may bind to and target the activated
protein kinase C preferentially to the phosphorylation sites on AC
catalysts and/or Gi/Gs (Mochly Rosen and Gordon, 1998). The
putative promotion of the cross-talk between Ca2+/protein kinase
C signals and AC may contribute to the enhanced Th2 cytokine
production in AD T cells (Table I), and thus the precise
mechanism(s) for the promotion should be elucidated in further
Figure 5. Correlation between anti-CD3/
CD28-induced cAMP increase and anti-
CD3/CD28-induced IL-4, IL-5, IFN-g, or IL-
2 secretion in AD and normal T cells. (a, b)
IL-4 secretion, (c, d) IL-5 secretion, (e, f) IFN-g
secretion, (g, h) IL-2 secretion. T cells from 15
AD patients and 14 normal donors were
incubated in anti-CD3 plus anti-CD28-precoated
plates. The intracellular cAMP level was analyzed
after 5 min, whereas cytokine secretion was
assayed after 48 h, and the background values
without anti-CD3/CD28 were subtracted. The
anti-CD3/CD28-induced increase of cAMP is
shown as the x-axis, whereas anti-CD3/CD28-
induced cytokine secretion is shown as the y-axis.
The 95% con®dence intervals are shown.
Background cAMP level and cytokine secretion
were described in the footnote for Table I.
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studies. Another possible mechanism is that anti-CD3/CD28 may
induce, to a greater extent, secondary signals, protein kinase C
activation, and/or intracellular Ca2+ signal in AD T cells than in
normal T cells, which may lead to greater AC activation in the
former. This possibility is, however, rather unlikely as IL-2 and
IFN-g production (which is more dependent on protein kinase C
than Th2 cytokine production) was not increased in AD T cells
compared with that in normal T cells.
Previous studies reported that azole derivatives reduced the
activity of AC; azole derivatives ketoconazole, itraconazole, and
miconazole inhibited basal and corticotropin-releasing hormone,
cholera toxin, NaF, or forskolin-stimulated AC activity in rat
anterior pituitary cells (Stalla et al, 1988, 1989). These reports
suggest that the azole derivatives may directly inhibit the activity of
AC catalytic subunit(s) and favor our present results. Azole
derivatives also inhibit membrane-associated AC activity of
Candida albicans by changing the conformation of the AC-
surrounding membrane microenvironment, such as membrane
¯uidity (Surarit and Shepherd, 1987). Opposing results were also
reported, however; ketoconazole alone and in synergy with
thyroid-stimulating hormone increased cAMP release from rat
thyroid cells, indicating the ketoconazole-induced stimulation of
AC (Kohan et al, 1992). Thus the effects of azole derivatives on AC
appeared to vary depending on the cell types. This is possibly
because the composition of AC isoforms differs with cell type and
azole derivatives may differentially inhibit some isoform(s) while
stimulating the other isoform(s). Thus the azole-inhibitable AC
isoform(s) should further be elucidated.
Azole derivatives did not alter the activity of PDE from human T
cells in this study. Discrepant results are, however, reported; azole
derivatives inhibited the activity of Ca2+/calmodulin-dependent
PDE (PDE type 1) derived from beef heart by interacting with
calmodulin (Hegemann et al, 1993). The discrepancy from our
present results may be due to the difference in PDE isoforms
depending on the cell and tissue types; the major PDE types in
normal human T cells are PDE3, 4, and 7, whereas PDE1 activity is
very low (Tenor et al, 1995; Giembycz et al, 1996; Erdogan and
Houslay, 1997; Li et al, 1999b). Hegemann et al (1993) also
reported that azole derivatives inhibited the activity of calmodulin-
independent (non-PDE1) PDE activity from the beef heart;
however, this effect only occurs at extremely higher concentra-
tions, e.g., IC50 262.5 mM for ketoconazole, and may not occur in
the concentration range (= 10 mM) used in our study.
In this study, PDE activity is slightly increased after anti-CD3/
CD28 stimulus, which may be due to the PKA activation by anti-
CD3/CD28-induced cAMP; it is reported that PKA phosphor-
ylates PDE4D3, which induces the rapid and reversible activation
of PDE4D3 (Sette and Conti, 1996). Terbina®ne hydrochloride
and tolnaftate further increased the PDE activity in anti-CD3/
CD28-stimulated T cells, which resulted in the suppression of
cAMP signal, although their cAMP-reducing effects were lower
than those of AC-inhibiting azole derivatives. There were few
reports regarding the effects of terbina®ne hydrochloride or
tolnaftate on PDE activity; treatment with tolnaftate did not alter
PDE activity of Microsporum gypseum cells (Gupta et al, 1991).
Tolnaftate did not alter the activity of PDE1 from beef heart
(Hegemann et al, 1993); however, the effects of tolnaftate or
terbina®ne hydrochloride on PDE or AC in human T cells have
not been precisely examined. We are now studying which PDE
isoform(s) may be stimulated by these drugs.
The activation of T cells with anti-CD3/CD28 on T cells
re¯ects the interaction with antigen-presenting cells, as antigen-
bound major histocompatibility complex molecules and B7
molecules on antigen-presenting cells interact with T cell
receptor/CD3 complexes and CD28 on T cells, respectively.
Thus the anti-mycotics may also suppress the Th2 cytokine
production of T cells, which interact with the cells presenting
allergens such as house dust mite, and this possibility is now under
investigation. In this study, azole and nonazole anti-mycotics
inhibited Th2 cytokine production at 0.01±1 mM with an optimal
concentration of 1 mM, which is close to the concentrations
obtained by the oral administration of these drugs; the peak serum
concentration was 0.71±0.85 mM for itraconazole (Warnock,
1989). It is thus indicated that these anti-mycotics may suppress
Th2 cytokine production in vivo. It has been recently reported that
Th2 cytokines, IL-4 and IL-5, drive the initial phase of AD, and
attract and activate macrophages or eosinophils in the skin lesions
(Grewe et al, 1998), whereas in a later phase IFN-g-producing T
cells predominantly in®ltrate and continue the in¯ammatory
responses (Thepen et al, 1996; Grewe et al, 1998). Thus the anti-
mycotics may prevent the initiation of atopic eczema rather than
suppress the ongoing skin in¯ammation. As patch tests with
aeroallergens such as house dust mites trigger Th2-skiewed
responses in the skin of AD patients (Sager et al, 1992), we should
further examine if anti-mycotics may inhibit the patch test reaction
Figure 6. The effects of anti-mycotics on anti-CD3/CD28-
induced mRNA expression for Th2 and Th1 cytokines. T cells
from an AD patient were preincubated for 30 min with medium alone
or with medium containing ketoconazole, terbina®ne hydrochloride, or
tolnaftate (each 1 mM), then seeded to anti-CD3 plus anti-CD28-
precoated plates, and incubated in the presence or absence of respective
anti-mycotics for another 6 h. RNA was extracted and reverse
transcription±PCR products were analyzed by electrophoresis (a) and the
intensity of the products was determined by densitometry (b). The data
represent ®ve separate experiments using T cells from ®ve different AD
patients.
1644 KANDA ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
to such aeroallergens in AD patients. A previous study reported that
topical treatment with ketoconazole suppressed erythematous
in¯ammatory skin reaction to heat-killed Staphylococcus aureus in
guinea-pigs (van Custem et al, 1991); however, there have been no
studies regarding the effects of anti-mycotics on patch test reactions
to aeroallergens. We should also examine if the anti-mycotics may
in vivo suppress Th2 cytokine production in AD patients by
comparing the Th1/Th2 cytokine pro®les between premedication
and postmedication and should also assess if these agents might
prevent the relapse of atopic eczema.
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